NCT05828446 Improving Hepatocellular Carcinoma Screening
| NCT ID | NCT05828446 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Naik Vietti Violi |
| Condition | Magnetic Resonance Imaging |
| Study Type | INTERVENTIONAL |
| Enrollment | 330 participants |
| Start Date | 2023-04-01 |
| Primary Completion | 2026-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 330 participants in total. It began in 2023-04-01 with a primary completion date of 2026-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a monocentric, single blind, interventional, single arm study. It is designed to compare the rates of detection of hepatocellular carcinoma (HCC) by ultrasound (US) used in clinical routine vs. abbreviated magnetic resonance imaging (AMRI). The hypothesis is that dynamic AMRI with extracellular contrast agent injection has a higher patient-level detection rate of HCC than screening US and non-contrast AMRI. Interested and eligible patients will be enrolled and undergo HCC screening rounds including US +/- contrast-enhanced US (clinical routine) and screening MRI within the same week bi-annually.
Eligibility Criteria
Inclusion Criteria: * All adult patients with chronic liver disease and indication for HCC screening according to the European Association for the Study of the Liver recommendations. * Informed Consent signed by the subject Exclusion Criteria: * History of HCC * History of other malignancy * Prior liver nodule categorized as LI-RAD 4, 5 or M * History of liver transplantation * Pregnancy * MRI or MRI contrast agent precaution * Any other condition making the patient unsuitable for the study * Patient's refusal of transmission of relevant medical conditions found on the medical examinations performed during the study
Contact & Investigator
Naik Vietti Violi, MD
PRINCIPAL INVESTIGATOR
University of Lausanne Hospitals
Frequently Asked Questions
Who can join the NCT05828446 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Magnetic Resonance Imaging. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05828446 currently recruiting?
Yes, NCT05828446 is actively recruiting participants. Contact the research team at naik.vietti-violi@chuv.ch for enrollment information.
Where is the NCT05828446 trial being conducted?
This trial is being conducted at Lausanne, Switzerland.
Who is sponsoring the NCT05828446 clinical trial?
NCT05828446 is sponsored by Naik Vietti Violi. The principal investigator is Naik Vietti Violi, MD at University of Lausanne Hospitals. The trial plans to enroll 330 participants.